Compare BridgeBio Pharma Inc (BBIO) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? BridgeBio Pharma Inc trades at $84.9 (market cap $16.46B), while iShares 10 20 Year Treasury Bond ETF trades at $98.14. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | TLH | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Fixed Income |
52-Week High | $90.17 | $105.36 |
52-Week Low | $44.81 | $97.13 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
TLH stock trades at $97.98, down 0.53% today, with a bearish technical signal from moving averages but bullish oscillators. The company has announced dividends for H1-26 and H2-26, yet key financial ratios are unavailable. Recent news highlights broader market volatility from Fed policy uncertainty and geopolitical tensions.
The outlook is cautious due to missing fundamental data and bearish technicals. Risks include macroeconomic headwinds and lack of visibility on earnings. Investment opportunity hinges on future financial disclosures and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
